Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros

Base de dados
País/Região como assunto
Ano de publicação
Tipo de documento
Intervalo de ano de publicação
1.
Gastroenterol Hepatol ; 45(3): 165-176, 2022 Mar.
Artigo em Inglês, Espanhol | MEDLINE | ID: mdl-34051313

RESUMO

OBJECTIVE: No studies evaluating the rapidity of response to biological therapies are available for Crohn's disease (CD). The aim of this study was to evaluate rapidity of onset of clinical response and impact on quality of life (QoL) of adalimumab therapy in adult anti-TNF-naïve patients with moderately-to-severely active CD. PATIENTS AND METHODS: RAPIDA was an open-label, single-arm, prospective, multicenter clinical trial. Adult patients with moderately-to-severely active luminal CD, anti-TNF-naïve, and unresponsive to conventional therapy were treated with adalimumab. Clinical disease activity, QoL and inflammatory biomarkers were measured at day 4, and weeks 1, 2, 4, and 12 after treatment initiation. RESULTS: Eighty-six patients were included in the intention-to-treat (ITT) analyses. Clinical disease activity was reduced from a median of 9.0 points to 6.0 points at day 4. Clinical response (≥ 3-point reduction in the Harvey-Bradshaw Index, HBI) was achieved by 61.6% (d4) and 75.6% (w1) of patients in the ITT population (median 2.5 days) and with non-responder imputation (NRI), by 55.8% and 53.4%, respectively. The proportion of patients in clinical remission (HBI<5) at weeks 2 and 4 in the ITT population was 54.7% and 62.8%, respectively (median 7.0 days), and 38.4% and 45.3% in the NRI population. All QoL scores significantly improved and inflammatory biomarkers significantly decreased from day 4 onwards (p<0.0001). CONCLUSION: Rapid clinical response and remission, improvement in QoL and fatigue, and a reduction of inflammatory biomarkers were achieved with adalimumab as early as day 4 in adult anti-TNF-naïve patients with moderately-to-severely active CD.


Assuntos
Adalimumab/uso terapêutico , Doença de Crohn/tratamento farmacológico , Qualidade de Vida , Inibidores do Fator de Necrose Tumoral/uso terapêutico , Adulto , Idoso , Biomarcadores/sangue , Doença de Crohn/sangue , Fadiga/tratamento farmacológico , Feminino , Humanos , Análise de Intenção de Tratamento , Masculino , Pessoa de Meia-Idade , Estudos Prospectivos , Indução de Remissão , Índice de Gravidade de Doença , Espanha , Fatores de Tempo , Resultado do Tratamento , Adulto Jovem
2.
ACS Macro Lett ; 8(10): 1391-1395, 2019 Oct 15.
Artigo em Inglês | MEDLINE | ID: mdl-35651154

RESUMO

A phenyltriazine compound has been used for the first time as a monomer in the construction of a hydrogel. This physically cross-linked soft material showed blue fluorescence when excited under UV-light. Polymer formation and intermolecular H-bonds arising from triazine moieties operate as aggregation-induced emission (AIE) mechanisms. The combination of soft materials and AIE properties expands the applications of these materials. As a proof of concept, two luminescent dyes have been incorporated into the hydrogel to produce a white-light-emitting material.

SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA